摘要
Abstract
Objective:To investigate the effect of cindilizumab combined with chemotherapy on advanced gastric cancer and the changes of tumor indexes.Method:According to random number table method,86 patients with gastric cancer treated in Yancheng NO.1 People's Hospital from February 2022 to January 2024 were divided into control group and monoclonal antibody group,with 43 cases in each group.The monoclonal antibody group was treated with Sintillizumab combined with chemotherapy,while the control group was treated with oxaliplatin plus capecitabine(XELOX).After 6 cycles of treatment,the safety,therapeutic effect,tumor indexes,serum transforming growth factor-β1(TGF-β1)and vascular endothelial growth factor(VEGF)levels were compared between the two groups.Result:There was no statistically significant difference in the incidence of toxic side effects between the two groups(P>0.05).After treatment,the objective efficacy of the monoclonal antibody group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 242,carbohydrate antigen 724,glycoprotein antigen 50 and carbohydrate antigen 199 in monoclonal antibody group were lower than those in control group,with statistical significance(P<0.05).After treatment,the levels of TGF-β1 and VEGF in monoclonal antibody group were lower than those in control group,and the differences were statistically significant(P<0.05).Conclusion:The combination of Sindilizumab and XELOX regimen in advanced gastric cancer patients can improve the therapeutic effect,regulate the level of tumor markers,serum TGF-β1 and VEGF levels,and has high safety.关键词
胃癌/信迪利单抗/化疗/肿瘤指标/治疗效果/安全性Key words
Gastric cancer/Cindilizumab/Chemotherapy/Tumor index/Therapeutic effect/Security
